Effective management of substance use disorder

Sarah Anwar, MDLinx

American Psychiatric Association 2018 Annual Meeting

New York, New York, United States | May 05-09, 2018

Advertisement

New York, NY, May 7, 2018—Screening all patients for substance use disorders should be part of all evaluations, according to Nora D. Volkow, MD, director, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, here at the American Psychiatric Association 2018 Annual Meeting.

“We have these preconceived notions about how a person suffering from a disease of addiction looks, we have an expectation, and say no. The psychiatrist may even feel uncomfortable asking the patient because addiction is stigmatized. We have to change that framework,” said Dr. Volkow.

Psychiatrists should also be prepared to prescribe buprenorphine and naltrexone (extended release also) in patients in whom they are indicated, or refer them to a methadone clinic, she added.

Advertisement